Hostname: page-component-669899f699-g7b4s Total loading time: 0 Render date: 2025-04-24T23:21:07.589Z Has data issue: false hasContentIssue false
  • English
  • Français

A Public Option for Clinical Trials? Lessons from Convalescent Plasma

Published online by Cambridge University Press:  31 May 2024

Victor Roy ,
Joseph S. Ross  and
Reshma Ramachandran
Victor Roy
Affiliation:
NATIONAL CLINICIAN SCHOLARS PROGRAM, DEPARTMENT OF INTERNAL MEDICINE, YALE SCHOOL OF MEDICINE
Joseph S. Ross
Affiliation:
NATIONAL CLINICIAN SCHOLARS PROGRAM, DEPARTMENT OF INTERNAL MEDICINE, YALE SCHOOL OF MEDICINE SECTION OF GENERAL INTERNAL MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, YALE SCHOOL OF MEDICINE DEPARTMENT OF HEALTH POLICY AND MANAGEMENT, YALE SCHOOL OF PUBLIC HEALTH YALE COLLABORATION FOR REGULATORY RIGOR, INTEGRITY, AND TRANSPARENCY, YALE SCHOOL OF MEDICINE
Reshma Ramachandran
Affiliation:
NATIONAL CLINICIAN SCHOLARS PROGRAM, DEPARTMENT OF INTERNAL MEDICINE, YALE SCHOOL OF MEDICINE SECTION OF GENERAL INTERNAL MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, YALE SCHOOL OF MEDICINE YALE COLLABORATION FOR REGULATORY RIGOR, INTEGRITY, AND TRANSPARENCY, YALE SCHOOL OF MEDICINE
Get access Rights & Permissions [Opens in a new window]

Abstract

The case of clinical trials for convalescent plasma during COVID-19 illustrates important lessons for realizing public sector approaches to biomedical research and development. These lessons, centering on mission, transparency, and spillover effects, can be translated to wider efforts to develop a “public option” for clinical trials.

Keywords

Clinical TrialsPublic OptionsMission-Oriented Innovation ModelsTransparencyConvalescent Plasma
Type
Commentary
Information
Journal of Law, Medicine & Ethics , Volume 52 , Issue 1 , Spring 2024 , pp. 98 - 100
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

National Academies of Science, Medicine, and Engineering. Envisioning a Transformed Clinical Trials Enterprise for 2030: Proceedings of a Workshop (National Academies Press; 2022), doi:10.17226/26349; Ross, J. S., et al., “Promoting Transparency in Pharmaceutical Industry — Sponsored Research,” American Journal of Public Health 102, no. 1 (2012): 72–80, doi:10.2105/AJPH.2011.300187.CrossRefGoogle ScholarPubMed
Grundy, Q. et al., “A Most Equitable Drug’: How the Clinical Studies of Convalescent Plasma as A Treatment for SARS-Cov-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug Development,” Journal of Law, Medicine & Ethics 52, no. 1 (2024): 80–97.CrossRefGoogle ScholarPubMed
Lewis, T. R. et al., “The Case for Public Funding and Public Oversight of Clinical Trials,” The Economists’ Voice 4, no. 1 (2007), doi:10.2202/1553-3832.1123.Google Scholar
Sitaraman, G. and Alstott, A. The Public Option: How to Expand Freedom, Increase Opportunity, and Promote Equality (Cambridge: Harvard University Press; 2019).Google Scholar
Sarpatwari, A., Brown, D., and Kesselheim, A. S. “Development of a National Public Pharmaceutical Research and Development Institute,” Journal of Law, Medicine & Ethics 48, no. 1 (2020): 225–227, doi:10.1177/1073110520917023; D. Baker “The Benefits and Savings from Publicly Funded Clinical Trials of Prescription Drugs,” International Journal of Health Services 38, no. 4 (2008): 731-50, doi: 10.2190/HS.38.4.i, PMID: 19069290.CrossRefGoogle ScholarPubMed
Cleary, E. Galkina, et al., “Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019,” JAMA Health Forum 4, no. 4 (2023): e230511, doi:10.1001/jamahealthforum.2023.0511.CrossRefGoogle Scholar
Mazzucato, M. and Roy, V., “Rethinking Value in Health Innovation: From Mystifications Towards Prescriptions, ”Journal of Economic Policy Reform 73, no. 2 (2018): 1–19, doi:10.1080/17487870.2018.1509712.Google Scholar
Kapczynski, A. et al., “How Not to Do Industrial Policy,” Boston Review, Published online October 2, 2023, available at <https://www.bostonreview.net/articles/how-not-to-do-industrial-policy/> (last visited March 5, 2024).+(last+visited+March+5,+2024).>Google Scholar
Normand, S. L. T., “The RECOVERY Platform,” New England Journal of Medicine 384, no. 8 (2021): 757–758, doi:10.1056/NEJMe2025674.CrossRefGoogle ScholarPubMed
Ross, J. S. and Malani, P., “Learning from the Success of the ACTIV Platform,” JAMA 330. No. 24 (2023): 2363–2364, doi:10.1001/jama.2023.24087.CrossRefGoogle ScholarPubMed
Eisenberg, P. et al., “Developing a Clinical Trials Infrastructure in the United States,” NAM Perspectives, Published online May 11, 2012, doi:10.31478/201205g.CrossRefGoogle Scholar
Patient Centered Outcomes Research Institute, Pragmatic Clinical Studies, Published August 1, 2016, available at <https://www.pcori.org/research/about-our-research/pragmatic-clinical-studies> (last visited March 5, 2024).+(last+visited+March+5,+2024).>Google Scholar